53 phenotypes from 31 alleles in 25 genetic backgrounds

Allelic Composition Genetic Background	Annotated Term	Reference
Gckem1(IMPC)H/Gck+ C57BL/6NTac-Gckem1(IMPC)H/H	impaired glucose tolerance	J:211773
	increased circulating alkaline phosphatase level	J:211773
	increased circulating fructosamine level	J:211773
	increased circulating glucose level	J:211773
	increased fasting circulating glucose level	J:211773
Gckem1(IMPC)H/Gckem1(IMPC)H C57BL/6NTac-Gckem1(IMPC)H/H	preweaning lethality, incomplete penetrance	J:211773
GckGena348/Gck+ involves: BALB/c * C3H/He	hyperglycemia	J:79719, J:82809, J:90389
	impaired glucose tolerance	J:90389
	increased body weight	J:82809
GckGena348/GckGena348 involves: BALB/c * C3H/He	hyperglycemia	J:90389
	impaired glucose tolerance	J:90389
GckGls006/Gck+ C3HeB/FeJ-GckGls006	decreased circulating insulin level	J:189544
	decreased glucokinase activity	J:189544
	decreased insulin secretion	J:189544
	decreased pancreatic beta cell mass	J:189544
	normal homeostasis/metabolism phenotype	J:189544
	hyperglycemia	J:189544
	impaired glucose tolerance	J:189544
	increased circulating glucose level	J:189544
	small pancreatic islets	J:189544
GckGls006/GckGls006 C3HeB/FeJ-GckGls006	abnormal pancreatic beta cell morphology	J:189544
	abnormal pancreatic islet morphology	J:189544
	decreased body weight	J:189544
	decreased glucokinase activity	J:189544
	decreased pancreatic beta cell mass	J:189544
	hyperglycemia	J:137483, J:189544
	increased circulating glucose level	J:189544
	normal mortality/aging	J:189544
	small pancreatic islets	J:189544
GckHlb62/? C57BL/6J-GckHlb62/J	hyperglycemia	J:82961, J:214141
	impaired glucose tolerance	J:214141
GckM1Btlr/Gck+ C57BL/6J-GckM1Btlr	impaired glucose tolerance	J:221479
GckM1Btlr/GckM1Btlr C57BL/6J-GckM1Btlr	impaired glucose tolerance	J:221479
Gckm1Rge/Gck+ involves: C3HeB/FeJ	decreased insulin secretion	J:162903
	decreased pancreatic beta cell mass	J:162903
	hyperglycemia	J:162903
	impaired glucose tolerance	J:162903
	increased circulating insulin level	J:162903
	insulin resistance	J:162903
	small pancreatic islets	J:162903
Gckm1Rge/Gckm1Rge involves: C3HeB/FeJ	decreased body weight	J:162903
	hyperglycemia	J:162903
	increased urine glucose level	J:162903
	postnatal growth retardation	J:162903
	postnatal lethality	J:162903
Gckm2Btlr/Gckm2Btlr C57BL/6J-Gckm2Btlr	impaired glucose tolerance	J:264650
GckRgsc149/Gck+ involves: C57BL/6J * DBA/2J	hyperglycemia	J:88919
	increased glycosylated hemoglobin level	J:88919
GckRgsc149/Gck+ involves: C57BL/6JJcl * DBA/2JJcl	hyperglycemia	J:133634
GckRgsc210/Gck+ involves: C57BL/6J * DBA/2J	hyperglycemia	J:88919
	impaired glucose tolerance	J:88919
	increased glycosylated hemoglobin level	J:88919
GckRgsc210/GckRgsc210 involves: C57BL/6J * DBA/2J	decreased body weight	J:88919
	decreased liver glycogen level	J:88919
	hepatic steatosis	J:88919
	hyperglycemia	J:88919
	increased urine glucose level	J:88919
	postnatal lethality	J:88919
GckRgsc236/Gck+ involves: C57BL/6J * DBA/2J	hyperglycemia	J:88919
	increased glycosylated hemoglobin level	J:88919
GckRgsc272/Gck+ involves: C57BL/6J * DBA/2J	decreased circulating insulin level	J:88919
	hyperglycemia	J:88919
	impaired glucose tolerance	J:88919
	increased glycosylated hemoglobin level	J:88919
GckRgsc341/Gck+ involves: C57BL/6J * DBA/2J	hyperglycemia	J:88919
	impaired glucose tolerance	J:88919
	increased glycosylated hemoglobin level	J:88919
GckRgsc392/Gck+ involves: C57BL/6J * DBA/2J	decreased circulating insulin level	J:88919
	hyperglycemia	J:88919
	impaired glucose tolerance	J:88919
	increased glycosylated hemoglobin level	J:88919
GckRgsc392/GckRgsc392 involves: C57BL/6J * DBA/2J	decreased body weight	J:88919
	decreased liver glycogen level	J:88919
	hepatic steatosis	J:88919
	hyperglycemia	J:88919
GckRgsc475/Gck+ involves: C57BL/6J * DBA/2J	decreased circulating insulin level	J:88919
	hyperglycemia	J:88919
	impaired glucose tolerance	J:88919
	increased glycosylated hemoglobin level	J:88919
GckRgsc552/Gck+ involves: C57BL/6J * DBA/2J	hyperglycemia	J:88919
	increased glycosylated hemoglobin level	J:88919
GckRgsc553/Gck+ involves: C57BL/6J * DBA/2J	hyperglycemia	J:88919
	increased glycosylated hemoglobin level	J:88919
GckRgsc702/Gck+ involves: C57BL/6J * DBA/2J	decreased circulating insulin level	J:88919
	hyperglycemia	J:88919
	impaired glucose tolerance	J:88919
	increased glycosylated hemoglobin level	J:88919
GckRgsc702/GckRgsc702 involves: C57BL/6J * DBA/2J	decreased body weight	J:88919
	decreased liver glycogen level	J:88919
	hepatic steatosis	J:88919
	hyperglycemia	J:88919
	increased urine glucose level	J:88919
	postnatal lethality	J:88919
GckRgsc735/Gck+ involves: C57BL/6J * DBA/2J	hyperglycemia	J:88919
	increased glycosylated hemoglobin level	J:88919
GckRgsc960/Gck+ involves: C57BL/6JJcl * DBA/2JJcl	hyperglycemia	J:133634
GckSgrd-2Nwu/Gck+ C57BL/6J-GckSgrd-2Nwu	hyperglycemia	J:196563
GckSgrd-2Nwu/GckSgrd-2Nwu C57BL/6J-GckSgrd-2Nwu	decreased circulating insulin level	J:196563
	hyperglycemia	J:196563
GckSgrd/Gck+ C57BL/6J-GckSgrd	decreased circulating insulin level	J:196563
	hyperglycemia	J:196563
GckSgrd/GckSgrd-2Nwu C57BL/6J-GckSgrd/GckSgrd-2Nwu	decreased circulating insulin level	J:196563
	hyperglycemia	J:196563
GckSgrd/GckSgrd C57BL/6J-GckSgrd	decreased circulating insulin level	J:196563
	hyperglycemia	J:196563
Gcktm1.1Mgn/Gck+ Tg(Ins2-cre)25Mgn/0 involves: 129S6/SvEvTac * C57BL/6 * DBA/2	decreased glycogen level	J:51826
	decreased insulin secretion	J:51826
	hyperglycemia	J:51826
	impaired glucose tolerance	J:51826
Gcktm1.1Mgn/Gcktm1.1Mgn 129S6/SvEvTac-Gcktm1.1Mgn	increased circulating glucose level	J:51826
Gcktm1.1Mgn/Gcktm1.1Mgn involves: 129S6/SvEvTac * C57BL/6	increased circulating glucose level	J:51826
Gcktm1.1Mgn/Gcktm1.1Mgn Speer6-ps1Tg(Alb-cre)21Mgn/Speer6-ps1+ involves: 129S6/SvEvTac * C57BL/6 * DBA/2	abnormal glucose homeostasis	J:51826
	decreased glycogen level	J:51826
	decreased insulin secretion	J:51826
	impaired glucose tolerance	J:51826
	increased circulating glucose level	J:51826
	increased circulating insulin level	J:51826
	insulin resistance	J:51826
Gcktm1.1Mgn/Gcktm1.1Mgn Tg(Ins2-cre)25Mgn/0 involves: 129S6/SvEvTac * C57BL/6 * DBA/2	decreased circulating insulin level	J:51826
	decreased liver glycogen level	J:51826
	hepatic steatosis	J:51826
	hyperglycemia	J:51826
	neonatal lethality, incomplete penetrance	J:51826
Gcktm1.2Mgn/Gck+ involves: 129S6/SvEvTac * C57BL/6	decreased insulin secretion	J:51826
	decreased liver glycogen level	J:51826
	hepatic steatosis	J:51826
	hyperglycemia	J:51826
	impaired glucose tolerance	J:51826
Gcktm1.2Mgn/Gcktm1.2Mgn involves: 129S6/SvEvTac * C57BL/6	decreased circulating insulin level	J:51826
	decreased liver glycogen level	J:51826
	hepatic steatosis	J:51826
	hyperglycemia	J:51826
	increased circulating free fatty acids level	J:51826
	postnatal lethality, complete penetrance	J:51826
Gcktm1Efr/Gck+ involves: 129P2/OlaHsd * C57BL/6	abnormal glucose homeostasis	J:28756
	hyperglycemia	J:28756
	impaired glucose tolerance	J:28756
Gcktm1Efr/Gcktm1Efr involves: 129P2/OlaHsd * C57BL/6	embryonic lethality during organogenesis, incomplete penetrance	J:28756
Gcktm1Hrt/Gck+ Speer6-ps1Tg(Alb-cre)21Mgn/Speer6-ps1+ involves: C57BL/6 * DBA	abnormal heart echocardiography feature	J:250069
	abnormal mitochondrial crista morphology	J:250069
	abnormal pancreatic beta cell physiology	J:250069
	cardiac fibrosis	J:250069
	impaired glucose tolerance	J:105247, J:250069
	increased circulating glucose level	J:105247
	increased fasting circulating glucose level	J:250069
	increased mitochondrial number	J:250069
	insulin resistance	J:250069
	prolonged PR interval	J:250069
	prolonged QRS complex duration	J:250069
Gcktm1Mgn/Gcktm1Mgn involves: 129S6/SvEvTac * C57BL/6	increased circulating glucose level	J:51826
Gcktm1Tka/Gck+ involves: 129X1/SvJ * ICR	decreased insulin secretion	J:30334
	hyperglycemia	J:30334
	impaired glucose tolerance	J:30334
	increased urine glucose level	J:30334
Gcktm1Tka/Gcktm1Tka involves: 129X1/SvJ * ICR	abnormal pancreatic beta cell physiology	J:30334
	decreased circulating insulin level	J:30334
	decreased insulin secretion	J:30334
	normal endocrine/exocrine gland phenotype	J:30334
	hepatic steatosis	J:30334
	hyperglycemia	J:30334
	increased urine glucose level	J:30334
	ketosis	J:30334
	postnatal growth retardation	J:30334
	postnatal lethality, complete penetrance	J:30334
Gcktm1Ts/Gck+ either: (involves: 129S7/SvEvBrd * C57BL/6J) or (involves: 129S7/SvEvBrd * DBA/2J)	hyperglycemia	J:29255
	impaired glucose tolerance	J:29255
Gcktm1Ts/Gcktm1Ts either: (involves: 129S7/SvEvBrd * C57BL/6J) or (involves: 129S7/SvEvBrd * DBA/2J)	abnormal circulating cholesterol level	J:29255
	decreased liver glycogen level	J:29255
	increased circulating triglyceride level	J:29255
	microvesicular hepatic steatosis	J:29255
	postnatal lethality, complete penetrance	J:29255
Gcktm1Ydor/Gck+ Tg(Ins2-cre)25Mgn/0 involves: C57BL/6 * C57BL/6J * DBA	abnormal endocrine pancreas physiology	J:302600
	abnormal pancreatic beta cell physiology	J:302600
	decreased fasting circulating glucose level	J:302600
	decreased pancreatic beta cell mass	J:302600
	hypoglycemia	J:302600
	impaired glucose tolerance	J:302600
	increased circulating insulin level	J:302600
	increased insulin secretion	J:302600
	increased pancreatic beta cell mass	J:302600
	increased pancreatic beta cell proliferation	J:302600
Gcktm1Ydor/Gck+ Tg(Ins1-cre/ERT)1Lphi/0 involves: C57BL/6 * C57BL/6J * CD-1	hypoglycemia	J:302600
	impaired glucose tolerance	J:302600
	increased pancreatic beta cell mass	J:302600
Gcktm2Mgn/Gck+ 129S6/SvEvTac-Gcktm2Mgn	abnormal glucose homeostasis	J:121910
	abnormal insulin secretion	J:121910
	decreased glucokinase activity	J:121910
	normal endocrine/exocrine gland phenotype	J:121910
	hyperglycemia	J:121910
	impaired glucose tolerance	J:121910
Gcktm2Mgn/Gck+ B6.129S6-Gcktm2Mgn	hyperglycemia	J:121910
Gcktm2Mgn/Gcktm2Mgn 129S6/SvEvTac-Gcktm2Mgn	hyperglycemia	J:121910
	postnatal lethality, complete penetrance	J:121910
Gcktm3Mgn/Gck+ 129S6/SvEvTac-Gcktm3Mgn	abnormal glucose homeostasis	J:121910
	abnormal insulin secretion	J:121910
	decreased glucokinase activity	J:121910
	normal endocrine/exocrine gland phenotype	J:121910
	hypoglycemia	J:121910
Gcktm3Mgn/Gck+ B6.129S6-Gcktm3Mgn	hypoglycemia	J:121910
Gcktm3Mgn/Gcktm3Mgn 129S6/SvEvTac-Gcktm3Mgn	abnormal circulating insulin level	J:121910
	abnormal glucose homeostasis	J:121910
	abnormal insulin secretion	J:121910
	decreased circulating glucose level	J:121910
	decreased glucokinase activity	J:121910
	hypoglycemia	J:121910